The NADINA trial presented at ASCO Annual Meeting showed that neoadjuvant immunotherapy with nivolumab plus ipilimumab extended event-free survival (EFS) for individuals with resectable stage III melanoma. This new approach resulted in 68% fewer events compared to standard treatment, with benefits also seen in patients with BRAF mutations. Neoadjuvant therapy produced major pathological responses in 59% of patients, leading to excellent outcomes. While there were more adverse events in the neoadjuvant arm, the results suggest that neoadjuvant immunotherapy followed by response-driven adjuvant therapy should be the new standard of care for macroscopic stage III melanoma.
Source link
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
